Ab interno cyclophotocoagulation (CPC) device demand — the MicroPulse P3 (Iridex), Cyclo G6 (IRIDEX), Endo-Optiks E2, and novel diode laser systems creating transscleral or endoscopic ciliary body photocoagulation for aqueous humor production reduction in refractory glaucoma representing the most destructive MIGS segment in the global minimally invasive glaucoma surgery device market — creates the most physiology-modifying market segment, with the Minimally Invasive Glaucoma Surgery Device Market reflecting CPC as the premium ciliary commercial driver.

Ciliary body physiology and aqueous production — the approximately 2.5-3.0 µL/minute aqueous humor production by ciliary body epithelium, with β-blockers (timolol, betaxolol) and carbonic anhydrase inhibitors (dorzolamide, brinzolamide) reducing production by 20-40%, and CPC creating 30-50% production reduction through ciliary process photocoagulation — demonstrates the physiological target. The ciliary body's accessibility through the sclera (transscleral) or pars plana (endoscopic) creating the surgical approach options.

MicroPulse P3 and transscleral micropulse technology — the Iridex MicroPulse P3 (810 nm diode laser, 33% duty cycle, 2.0 W power, 2-minute treatment per hemisphere, non-contact probe) creating FDA-approved transscleral CPC with 10-15 mmHg IOP reduction and 40-50% medication reduction in refractory glaucoma — demonstrates the micropulse innovation. The MicroPulse technology's ability to deliver sub-threshold thermal energy, avoiding continuous-wave coagulative damage, reducing inflammation and hypotony risk, and enabling retreatment creating the safety profile.

Endoscopic cyclophotocoagulation (ECP) and direct visualization — the Endo-Optiks E2 and IRIDEX EndoProbe creating 810 nm diode laser delivery via endoscopic fiberoptic (20-gauge, 175-200° field) with direct ciliary process visualization, selective photocoagulation, and immediate efficacy assessment — demonstrates the endoscopic precision. The ECP's ability to titrate energy delivery, spare adjacent tissue, and combine with cataract surgery or other MIGS creating the versatility.

Do you think MicroPulse CPC will eventually replace continuous-wave transscleral CPC and ECP as the standard ciliary body treatment, or will the established efficacy, lower cost, and simplicity of continuous-wave and the precision of ECP maintain multiple CPC modalities for different clinical scenarios?

What cyclophotocoagulation devices are available for MIGS? Transscleral: MicroPulse P3 (Iridex) — 810 nm diode; 33% duty cycle; 2.0 W power; 2 minutes/hemisphere; Non-contact probe; FDA: refractory glaucoma; IOP reduction: 10-15 mmHg; Medication: 40-50% reduction; Repeatable; Continuous-wave CPC: IRIDEX G-Probe — 810 nm; Contact probe; 1.5-2.5 W; 2 seconds/spot; 270° treatment; Higher complication rate; Rarely used now; Endoscopic: Endo-Optiks E2 — 810 nm diode; 20-gauge endoscope; 175-200° field; Direct visualization; Selective coagulation; Combine with phaco/MIGS; IOP reduction: 8-12 mmHg; IRIDEX EndoProbe — Similar; Key specifications: Wavelength: 810 nm (diode); 1064 nm (Nd:YAG, limited); Power: 1.5-2.5 W (continuous); 2.0 W (MicroPulse); Duration: 2 seconds/spot (continuous); 2 minutes/hemisphere (MicroPulse); Spots: 18-24 (continuous); Coverage: 270° (3/4 ciliary body); 360° (full); Treatment: One or two sessions; Outcomes: IOP: 14-18 mmHg (target); 10-15 mmHg reduction; Medications: 0-2 drops; 40-50% reduction; Success: 60-70% at 2 years; Complications: Hypotony: 5-10% (continuous); <5% (MicroPulse); Inflammation: 20-30%; Cystoid macular edema: 5-10%; Phthisis: 1-2% (continuous); <1% (MicroPulse); Vision loss: 5-10% (continuous); <5% (MicroPulse); Comparison to trabeculectomy: Efficacy: CPC: 10-15 mmHg; Trabeculectomy: 15-25 mmHg; Safety: CPC: fewer bleb complications; Trabeculectomy: bleb-related issues; Recovery: CPC: 1-2 weeks; Trabeculectomy: 4-6 weeks; Repeatability: CPC: yes (MicroPulse); Trabeculectomy: limited.

What is the market size and refractory impact for CPC devices? Market metrics: CPC devices: $80-150 million (2024); 5-10% of MIGS device market; MicroPulse P3: $60-100 million; ECP: $15-30 million; Continuous-wave: $5-10 million (declining); Growth: 8-10% CAGR; Refractory glaucoma: 10-15% of glaucoma patients; 300,000-500,000 US patients; CPC penetration: 15-20% of refractory; Trabeculectomy: 50-60%; Tube shunts: 20-30%; Pricing: MicroPulse P3 probe: $500-800 (disposable); Console: $15,000-25,000; ECP system: $20,000-35,000; Endo-Optiks E2: $25,000-40,000; Procedure: $2,000-4,000; Reimbursement: CPT 66710 — ECP; $600-900 physician; CPT 66711 — transscleral; $500-800 physician; Facility: $1,500-3,000; Medicare: covered; Commercial: prior auth; Key suppliers: Iridex — MicroPulse P3, market leader, 60-70%; Endo-Optiks — ECP, 15-20%; IRIDEX — continuous-wave, G-Probe, 10-15%; Others — 5-10%; Market drivers: Refractory glaucoma, failed trabeculectomy, neovascular glaucoma, silicone oil glaucoma, aphakic glaucoma, safety profile, repeatability, MicroPulse technology; Challenges: Vision loss risk (historical), inflammation, CME, variable efficacy, patient selection, reimbursement, competition with tube shunts, learning curve; Trends: MicroPulse dominance, ECP combination, repeatability, earlier intervention, pediatric glaucoma, nanosecond laser, personalized energy delivery, telemedicine follow-up.

#MIGS #Cyclophotocoagulation #MicroPulseP3 #ECP #EndoscopicCPC #RefractoryGlaucoma #CiliaryBody #Iridex #GlaucomaLaser